ARTICLE | Clinical News
Kyowa submits NDA in Japan for evocalcet in secondary hyperparathyroidism
July 21, 2017 1:01 AM UTC
Kyowa Hakko Kirin Co. Ltd. (Tokyo:4151) submitted an NDA in Japan for evocalcet (KHK7580, MT-4580) to treat secondary hyperparathyroidism in maintenance dialysis patients. Kyowa has rights to co-devel...